Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 17:12:639920.
doi: 10.3389/fphys.2021.639920. eCollection 2021.

TFEB: A Emerging Regulator in Lipid Homeostasis for Atherosclerosis

Manman Li  1 , Zitong Wang  1 , Pengyu Wang  1 , Hong Li  1 , Liming Yang  2
Affiliations
Review

TFEB: A Emerging Regulator in Lipid Homeostasis for Atherosclerosis

Manman Li et al. Front Physiol. .

Abstract

Atherosclerosis, predominantly characterized by the disturbance of lipid homeostasis, has become the main causation of various cardiovascular diseases. Therefore, there is an urgent requirement to explore efficacious targets that act as lipid modulators for atherosclerosis. Transcription factor EB (TFEB), whose activity depends on post-translational modifications, such as phosphorylation, acetylation, SUMOylation, ubiquitination, etc., is significant for normal cell physiology. Recently, increasing evidence implicates a role of TFEB in lipid homeostasis, via its functionality of promoting lipid degradation and efflux through mediating lipophagy, lipolysis, and lipid metabolism-related genes. Furthermore, a regulatory effect on lipid transporters and lipid mediators by TFEB is emerging. Notably, TFEB makes a possible therapeutic target of atherosclerosis by regulating lipid metabolism. This review recapitulates the update and current advances on TFEB mediating lipid metabolism to focus on two intracellular activities: a) how cells perceive external stimuli and initiate transcription programs to modulate TFEB function, and b) how TFEB restores lipid homeostasis in the atherosclerotic process. In-depth research is warranted to develop potent agents against TFEB to alleviate or reverse the progression of atherosclerosis.

Keywords: TFEB; atherosclerosis; lipid homeostasis; lipid mediators; lipid transporters; lipophagy; post-translational modifications.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The structure and function of TFEB in lipid homeostasis. TFEB is a protein consisting of 476 amino acid residues, mainly including glutamine-rich (GIn rich), an acidic transcription activation domain (AD), basic helix-loop-helix leucine-zipper (bHLHZIP) structure, and proline-rich motifs (Pro rich). Phosphorylation and acetylation are the most important post-translational modifications to regulate TFEB activity. The phosphorylated or acetylated TFEB sites by different proteins are shown in the figure. TFEB is also regulated by transcription and non-coding RNA. MicroRNA-128 targets TFEB to tune the transcription of autophagy-related genes. Methyltransferase like 3 (METTL3) inhibits the transcriptional activity of TFEB by methylating two m6A residues. After being activated into the nucleus, TFEB regulates downstream autophagy-lysosomal genes to modulate lipophagy and neutral lipolysis. Furthermore, TFEB also regulates lipid transport processes such as lipid uptake and cholesterol efflux by CD36 and ATP-binding cassette transporter A1(ABCA1).
See this image and copyright information in PMC

References

    1. Alghamdi T. A., Majumder S., Thieme K., Batchu S. N., White K. E., Liu Y., et al. (2017). Janus kinase 2 regulates transcription factor eb expression and autophagy completion in glomerular podocytes. J. Am. Soc. Nephrol. 28 2641–2653. 10.1681/asn.2016111208 - DOI - PMC - PubMed
    1. Argani P., Laé M., Hutchinson B., Reuter V. E., Collins M. H., Perentesis J., et al. (2005). Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am. J. Surg. Pathol. 29 230–240. 10.1097/01.pas.0000146007.54092.37 - DOI - PubMed
    1. Argani P., Reuter V. E., Zhang L., Sung Y. S., Ning Y., Epstein J. I., et al. (2016). TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am. J. Surg. Pathol. 40 1484–1495. 10.1097/pas.0000000000000720 - DOI - PMC - PubMed
    1. Bao J., Zheng L., Zhang Q., Li X., Zhang X., Li Z., et al. (2016). Deacetylation of TFEB promotes fibrillar Aβ degradation by upregulating lysosomal biogenesis in microglia. Protein Cell 7 417–433. 10.1007/s13238-016-0269-2 - DOI - PMC - PubMed
    1. Bodas M., Pehote G., Silverberg D., Gulbins E., Vij N. (2019). Autophagy augmentation alleviates cigarette smoke-induced CFTR-dysfunction, ceramide-accumulation and COPD-emphysema pathogenesis. Free Radic. Biol. Med. 131 81–97. 10.1016/j.freeradbiomed.2018.11.023 - DOI - PubMed

LinkOut - more resources